Facultés Universitaires Catholiques de Mons

EDEN PRAIRIE, Minn., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced CEO Jeff Ross will present at the Bioregate European Regenerative Medicine Forum. The conference, held this year on September 21-23 in Louvain-la-Neuve, Belgium, is dedicated to the 4R Medicine, Repair, Replacement, Regeneration, and Reprogramming. Mr. Ross will be a keynote speaker at the Bioregate European Regenerative Medicine Forum on September 21st, 2022 at 3:05 pm CEST. The event is organized by Nantes University, the Catholic University of Louvain and Atlanpole Biotherapies, with the support of the University of Liège, FlandersBio, BioWin, Wallonie-Bruxelles International, FNRS, the Region of Pays de la Loire and Nantes Métropole. About Miromatrix Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visit miromatrix.com. Investor Contact Greg Chodaczek 347-620-7010 ir@miromatrix.com Media Contact: press@miromatrix.com

Collaboration with Leading Authority on SOI Technologies Will Explore the Commercial Potential of Acorn Process Manufacturing Innovations in RF Applications LA JOLLA, Calif.--(BUSINESS WIRE)-- Acorn Technologies, a groundbreaking innovator in the semiconductor and telecommunications markets since 1998, today announced a research collaboration with Jean-Pierre Raskin, PhD, a full professor at the Université catholique de Louvain (UCLouvain), Belgium's largest French-speaking university. Acorn is funding a research project led by Professor Raskin to assess and quantify the performance potential of the company’s Acorn Buried Stressor (ABS) technology for RF semiconductor manufacturing. As today’s system and circuit designers approach the limits of Moore’s Law, Acorn is addressing some of the semiconductor industry’s most significant technology roadblocks through multiple commercialization programs. Acorn’s ABS is a proprietary semiconductor strain technology that boosts performance for both legacy and future fully depleted Silicon-on-Insulator (FD-SOI) devices. FD-SOI technology is a planar process developed to shrink silicon geometries, improve performance and reduce power, thereby extending Moore's Law without requiring more complicated manufacturing processes. ABS extends the performance and efficiency of ultra-high frequency RF FD-SOI transistors that operate in the hundreds of gigahertz and are essential for 5G and future 6G communications devices. ABS can also be applied to Acorn’s patented germanium laser technology, which provides a silicon-compatible solution for monolithic photonics-on-a-chip to overcome performance-limiting interconnect bottlenecks that cause excessive power consumption. “Acorn’s ABS technology holds great promise for the semiconductor industry as a novel technique for enhancing the performance of FD-SOI devices,” said Professor Jean-Pierre Raskin. “I look forward to working closely with Acorn’s engineering team as we evaluate and quantify the capabilities of ABS for potential commercial use in a wide range of RF applications.” A world-renowned expert in RF and FD-SOI technologies, Professor Raskin has collaborated with many of the world’s top semiconductor companies in multiple research projects. He has pioneered important breakthroughs that have been adopted by the FD-SOI sector of the semiconductor industry as an alternative to FinFET technology, with a focus on low-power mobile chipsets used in smartphones and other mobile connected devices. “We are honored to collaborate with Professor Raskin as we explore the benefits of applying ABS to accelerate the performance of RF devices manufactured with FD-SOI technology,” said Tom Horgan, CEO of Acorn. “We believe Professor Raskin and his distinguished UCLouvain research team will add tremendous value to Acorn’s efforts to commercialize process manufacturing innovations for the benefit of the entire semiconductor industry.” “ABS technology can provide a 15 to 25 percent performance boost for RF FD-SOI devices by increasing the electron mobility through strain. This is accomplished without performance trade-offs and without adverse effects such as yield-threatening semiconductor layer defects. As RF transistors are now reaching the limits of geometric scaling, further improvements will only come from materials enhancement technologies such as ABS,” said Paul Clifton, VP of semiconductor technologies at Acorn. “Our research project with Professor Raskin will provide invaluable insights as we expand the commercial application of ABS in FD-SOI for next-generation radio technologies including advanced 5G, mmWave and future 6G opportunities.” About Jean-Pierre Raskin Jean-Pierre Raskin has contributed to groundbreaking scientific research demonstrating that Silicon-on-Insulator (SOI) technology can enable affordable, high-performance mobile devices. His findings led to the advent of RF-SOI technology, which has been widely adopted by the global microelectronics industry. The author or co-author of more than 350 scientific articles, Professor Raskin is an IEEE Fellow, an EuMA associate member, and a member of the Research Center in Micro and Nanoscopic Materials and Electronic Devices at the Université catholique de Louvain (UCLouvain), where he has been a full professor since 2007. He received an industrial engineer degree from the Institut Supérieur Industriel d’Arlon and M.S. and Ph.D. degrees in applied sciences from UCLouvain. About Acorn Technologies Inc. Acorn Technologies is a product-oriented company that has been providing groundbreaking innovations for the semiconductor and telecom markets since 1998. Through its subsidiaries Acorn Semi and PHY Wireless, Acorn Technologies delivers innovative IP cores, algorithms, processes, and products that address the fundamental building blocks of high-performance mobile computing, wireless, and IoT semiconductor devices.

GENEVA, Switzerland and BOSTON, MA – April 30, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN) a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of five e-Posters on linzagolix in the treatment of uterine fibroids at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting (ACSM), which will take place virtually from April 30 to May 2, 2021. The data presented further substantiate the best-in-class potential of linzagolix for the treatment of heavy menstrual bleeding (HMB) due to uterine fibroids addressing both key efficacy and safety parameters from the PRIMROSE Phase 3 program. The posters being presented, along with lead authors and key conclusions are: Poster #196: Effects of the oral GnRH antagonist linzagolix on uterine and fibroid volume in two Phase 3 trials Lead author: Jacques Donnez, MD, PhD; Professor, Société de Recherche pour l'Infertilité (SRI), Brussels and Catholic University of Louvain, Belgium Key Conclusions: The 200 mg dose of linzagolix without hormonal add-back therapy (ABT) was the only dose to show consistent substantial and significant reductions in uterine and fibroid volumes. Linzagolix is the only GnRH antagonist with a high-dose non-ABT option with the potential for short-term use for reduction of uterine and fibroid volume. Poster #231: Impact of linzagolix on pain in patients with fibroid-related heavy menstrual bleeding: results of two Phase 3 trials Lead author: Ayman Al-Hendy, MD, PhD; Professor, Department of Obstetrics and Gynecology, University of Chicago Key Conclusions: Linzagolix 100 and 200 mg, with and without ABT, consistently improved pain in women with fibroid-associated HMB.  Pain reduction in the treatment groups was achieved after 12 weeks and was maintained up to 52 weeks.  By 12 weeks following termination of treatment, pain scores had increased but had not reached baseline levels. Poster #2962: Impact of linzagolix treatment on anemia in women with uterine fibroid related heavy menstrual bleeding:  results of two Phase 3 clinical trials Lead author: William Catherino, MD, PhD; Professor, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences Key Conclusions: High and low linzagolix doses with and without ABT improved hemoglobin and ferritin levels in anemic women with uterine fibroids.  In the 12-week follow-up period hemoglobin levels decreased but did not return to baseline levels. Poster #194: Safety of linzagolix in the treatment of women with uterine fibroids: Results from two Phase 3 clinical trials Lead author: Hugh Taylor, MD; Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine Key Conclusions: Overall treatment emergent adverse event (TEAE) rates at 24 weeks were similar to placebo for the linzagolix 100 mg and 200 mg with ABT regimens. Lumbar spine bone mineral density (BMD) z-scores indicated no change in risk categories. TEAE rates at Week 24 and BMD up to 52 weeks support the potential for long term use of linzagolix 100 mg and 200 mg with ABT. Poster #1868: Impact of linzagolix on events of depression and other mood disorders in women with uterine fibroidsLead author: Robert Taylor, MD, PhD; Professor, Obstetrics and Gynecology, University at Buffalo Key Conclusions: In the Phase 3 uterine fibroids trials of linzagolix, the incidence of depression and other mood disorder adverse events was low and revealed no consistent drug-related pattern. All ePosters will be displayed on the ACOG Annual Meeting virtual platform in gallery view with search features by title, topic, and category. Each ePoster will have a dedicated page that will include a 5-minute prerecorded ePoster preview. About Uterine Fibroids Uterine fibroids are common benign tumors of the muscular tissue of the uterus. Uterine fibroids affect women of childbearing age and can vary in size from undetectable to large bulky masses. Few long-term medical treatments are available, and as a result, approximately 300,000 hysterectomies are performed for uterine fibroids every year in the US. The symptoms of uterine fibroids are wide-ranging and include heavy menstrual bleeding, anemia, pelvic pressure and bloating, urinary frequency and pain that can be extremely debilitating with a significant impact on quality of life. These symptoms can also have an impact on mental health, creating the additional burden of anxiety and distress. About ObsEva ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit . About Yselty® (Linzagolix) Yselty® (linzagolix) is a novel, once daily, oral GnRH receptor antagonist with a potentially best-in-class profile. Linzagolix is currently in late-stage clinical development for the treatment of heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis. ObsEva licensed linzagolix from Kissei in late 2015 and retains worldwide commercial rights, excluding Asia, for the product. Linzagolix is not currently approved anywhere in the world. About Kissei Kissei is a Japanese pharmaceutical company with approximately 70 years of history, specialized in the field of urology, kidney-dialysis and Unmet Medical Needs. Silodosin is a Kissei product for the treatment of the signs and symptoms of benign prostatic hyperplasia which is sold worldwide through its licensees. KLH-2109/OBE2109 is a new chemical entity discovered by Kissei R&D. Cautionary Note Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and other similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the potential therapeutic benefits and the clinical development of ObsEva’s product candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, the impact of the novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2020 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at . Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. For further information, please contact: CEO Office contactShauna DillonShauna.dillon@obseva.ch+41 22 552 1550 Investor Contact:Joyce Allaire jallaire@lifesciadvisors.com+1 (617) 435-6602 Attachment